

Resource Summary Report

Generated by [NIF](#) on Aug 30, 2026

A-498

RRID:CVCL_1056

Type: Cell Line

Proper Citation

RRID:CVCL_1056

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1056

Proper Citation: RRID:CVCL_1056

Description: Cell line A-498 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Renal cell carcinoma

Defining Citation: [PMID:327080](#), [PMID:375235](#), [PMID:450131](#), [PMID:571047](#), [PMID:833871](#), [PMID:2041050](#), [PMID:3335022](#), [PMID:4357758](#), [PMID:6173755](#), [PMID:6244232](#), [PMID:6401685](#), [PMID:6825208](#), [PMID:6935474](#), [PMID:6954533](#), [PMID:7459858](#), [PMID:7915601](#), [PMID:8493574](#), [PMID:9331090](#), [PMID:9488600](#), [PMID:10700174](#), [PMID:10723130](#), [PMID:10929426](#), [PMID:11146448](#), [PMID:15585611](#), [PMID:15604581](#), [PMID:15748285](#), [PMID:17088437](#), [PMID:17409424](#), [PMID:19372543](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:22068913](#), [PMID:22282976](#), [PMID:22347499](#), [PMID:22384151](#), [PMID:22460905](#), [PMID:22628656](#), [PMID:22949125](#), [PMID:23856246](#), [PMID:23933261](#), [PMID:24279929](#), [PMID:24670534](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26589293](#), [PMID:26759240](#), [PMID:26972028](#), [PMID:27141528](#), [PMID:27377824](#), [PMID:27397505](#), [PMID:27807467](#), [PMID:27993170](#), [PMID:28196595](#), [PMID:28489074](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31733513](#), [PMID:31978347](#), [PMID:35839778](#), [PMID:38861359](#)

Comments: Population: Caucasian., Part of: NCI-60 cancer cell line panel., Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982)., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: A-498

Synonyms: A498

Cross References: BTO:BTO_0003769, CLO:CLO_0001596, CLO:CLO_0009974, EFO:EFO_0002105, CLDB:cl163, CLDB:cl164, CLDB:cl5025, CLDB:cl7160, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-7908, ATCC:HTB-44, BCRC:60241, BioSample:SAMN03471119, BioSample:SAMN03472919, BioSample:SAMN03473534, BioSample:SAMN10987879, cancercellines:CVCL_1056, CCRID:1101HUM-PUMC000171, Cell_Model_Passport:SIDM00124, ChEMBL-Cells:ChEMBL3308425, ChEMBL-Targets:ChEMBL614516, CLS:300113, Cosmic:687937, Cosmic:735612, Cosmic:845930, Cosmic:849378, Cosmic:874610, Cosmic:877453, Cosmic:905948, Cosmic:972874, Cosmic:972928, Cosmic:974301, Cosmic:982277, Cosmic:1092590, Cosmic:1152531, Cosmic:1175849, Cosmic:1305373, Cosmic:1312361, Cosmic:1995335, Cosmic:1998432, Cosmic:2520636, Cosmic:2653897, Cosmic:2663797, Cosmic-CLP:905948, DepMap:ACH-000555, DSMZ:ACC-55, DSMZCellDive:ACC-55, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:905948, GEO:GSM2132, GEO:GSM50227, GEO:GSM50291, GEO:GSM743481, GEO:GSM750836, GEO:GSM799372, GEO:GSM799435, GEO:GSM843438, GEO:GSM846284, GEO:GSM886856, GEO:GSM887921, GEO:GSM1153445, GEO:GSM1181297, GEO:GSM1181323, GEO:GSM1669587, GEO:GSM2124636, IARC_TP53:21036, ICLC:HTL04005, IGRhCellID:A498, IZSLER:BS TCL 111, KCLB:30044, LiGeA:CCLE_161, LINC_S_LDP:LCL-1761, Lonza:1198, NCI-DTP:A498, PharmacDB:A498_47_2019, PRIDE:PXD003105, PRIDE:PXD003539, PRIDE:PXD005942, PRIDE:PXD005946, PRIDE:PXD030304, Progenetix:CVCL_1056, PubChem_Cell_line:CVCL_1056, SKY/M-FISH/CGH:2783, TOKU-E:478, Wikidata:Q54606041

ID: CVCL_1056

Record Creation Time: 20220427T215104+0000

Record Last Update: 20260830T001939+0000

Ratings and Alerts

No rating or validation information has been found for A-498.

Warning: Discontinued: ATCC; CRL-7908

Population: Caucasian., Part of: NCI-60 cancer cell line panel., Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982)., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 858 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Wang C, et al. (2026) USP18 promotes clear cell renal cell carcinoma progression by regulating the ubiquitination and stability of YBX3. *iScience*, 29(5), 115808.

Liu Z, et al. (2026) ERMP1 Exerts Tumor-Suppressive Functions in KIRC by Inhibiting PI3K/AKT Signaling and Remodeling the Immune Microenvironment: A Pan-Cancer Analysis. *Human mutation*, 2026, 7717815.

Heritz JA, et al. (2026) Targeting and dissociating HIF2?? from the molecular chaperone Hsp70 triggers apoptosis in kidney cancer. *Communications medicine*, 6(1), 91.

Liao C, et al. (2026) Selective degradation of TBK1 uncovers mechanistic insights into blocking ccRCC progression. *Cell chemical biology*, 33(4), 461.

Becker PN, et al. (2026) 2,3-Bisphosphoglycerate Mutase (BPGM), a Metabolic Player Shaping Stress-Adaptive Transcriptional States in Clear Cell Renal Cell Carcinoma. *Cells*, 15(7).

Yang T, et al. (2026) Molecular Glue cc-885 Inhibits VHL-Deficient Clear Cell Renal Cell Carcinoma via ETS1 Degradation. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 13(42), e20237.

Li S, et al. (2026) Optimization of hinge domain enhances antitumor efficacy of globo H-targeted CAR-T cells in solid tumor models. *iScience*, 29(7), 116580.

Li G, et al. (2026) Mitochondrial VHL rewires cell metabolism in hypoxia. *Cell metabolism*, 38(1), 174.

Zhang B, et al. (2026) RB-BC: A Novel Ribociclib Derivative Targeting p53-Mediated Apoptosis and Inhibition of Tumor Growth in Breast Cancer. *Chemistry & biodiversity*, 23(2), e02267.

Abou Alaiwi S, et al. (2026) Generation of a comprehensive epigenomic atlas in clear cell renal cell carcinoma informs kidney cancer progression and heritability. *Cell reports*, 45(2), 116968.

Jing Y, et al. (2026) A TXNIP-driven bioluminescent reporter for high-throughput discovery of glycolytic inhibitors against renal cell carcinoma. *BMC biotechnology*, 26(1).

Garinet S, et al. (2026) Cell-free DNA epigenomic profiling enables noninvasive detection and monitoring of translocation renal cell carcinoma. *The Journal of clinical investigation*, 136(3).

Ni J, et al. (2026) CD70 regulates the NF1/Ras/ERK axis to promote metastatic potential in clear cell renal cell carcinoma. *Cancer cell international*, 26(1).

Koh J, et al. (2026) ZNF395 Is a Hypoxia-Responsive Regulator of Mitochondrial Glutaminolysis in Clear Cell Renal Cell Carcinoma. *Cancer research*, 86(7), 1676.

Chen Y, et al. (2026) USP15 stabilizes c-Myc to drive sunitinib resistance by suppressing cuproptosis in clear cell renal cell carcinoma. *Cell reports*, 45(5), 117328.

Shi H, et al. (2026) OSCAR functions as a collagen I receptor to suppress hippo signaling and reprogram lipid metabolism in clear-cell renal cell carcinoma. *Cell death & disease*, 17(1).

Koochaki P, et al. (2026) Structure-guided optimization of SLC1A1/EAAT3-selective inhibitors targeting renal cancer metabolism. *The EMBO journal*, 45(11), 3763.

Lee JS, et al. (2025) An ultraconserved snoRNA-like element in long noncoding RNA CRNDE promotes ribosome biogenesis and cell proliferation. *Molecular cell*, 85(8), 1543.

Grimm SL, et al. (2025) CA-125 as a Biomarker in Renal Medullary Carcinoma: Integrated Molecular Profiling, Functional Characterization, and Prospective Clinical Validation. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(6), 1057.

Schiele P, et al. (2025) CD8⁺ T cell-derived CD40L mediates noncanonical cytotoxicity in CD40-expressing cancer cells. *Science advances*, 11(21), eadr9331.